Contributions
Abstract: P468
Type: Poster
Abstract Category: Pathology and pathogenesis of MS - Progressive MS
Introduction: Primary progressive MS (PPMS) is a MS variant without treatment at the date in which the gait alterations represent the main source of disability. Fampridine was approved based on the improvement in walking speed as measured by 25FWT for MS patients. We hypothesize that fampridine would produce changes in a number of angular joint movements during gait cycle to allow improvement in translation capacity and balance.
Objectives: To analyze the response to Fampridine in PPMS patients by evaluating the spatio-temporal changes measured by instrumental gait analysis (IGA).
Material and methods: 10 PPMS patients were analyzed by IGA and 12 speed standard spatial parameters in both right (R) and left (L) leg were recorded: normalized speed according leg length(VN), cadence (C), total time support (% TTA) -% of gait cycle and its distribution among one leg (AM) and first (% 1FS) and second double support (% 2DS). Results were compared to 12 healthy controls matched by age. Improvement was defined as approximate values to normal and was measured by the difference between the absolute values of Z-score pre-treatment and those obtained after 15 days of starting treatment with fampridine. The confidence interval was calculated at 95% average improvement bootstrap accelerated corrected for bias.
Results: After 15 days of daily treatment with fampridine most of the Z-score of all spatial variables improved statistically significantly except % 1FS (R) and % AM (R). The improvement is 0.69(L) / 0.41(R) VN, 1.21(L) / 0.83 (R) for C, 1.30 (L) / 1.34 (R) % TTA, 0.61(L) / 0.68(R)% 1FS, 0.32 (L) / 0.13 (R)% AM, and 0.19 (L) / 0,13 (R) for% 2DS.
Conclusions: Treatment with Fampridinedemonstrates a statically improvement in cadence, total time support and 2nd double support in both legs, and first double support time in left leg. These changes imply greater stability and balance during the stay and gait after treatment administration.
Disclosure:
Gonzalez Suárez I has received funding form Novartis, Biogen and Genzyme.
Pulido-VAldeolivas I: nothing to disclosure
Gomez-Andrés D: nothing to disclosure
Orviz-Garcia A: has received funding from Novartis
Montero-Atalaya A: nothing to disclosure
Martin-Gonzalo JA: nothing to disclosure
Rodríguez-Andonaegui I: nothing to disclosure
López de Velasco V has received funding form Genzyme
Rausell-tamayo E: nothing to disclosure
Oreja-Guevara C: has received fundings form Novartis, Genzyme, Biogen, Roche, Merck
Abstract: P468
Type: Poster
Abstract Category: Pathology and pathogenesis of MS - Progressive MS
Introduction: Primary progressive MS (PPMS) is a MS variant without treatment at the date in which the gait alterations represent the main source of disability. Fampridine was approved based on the improvement in walking speed as measured by 25FWT for MS patients. We hypothesize that fampridine would produce changes in a number of angular joint movements during gait cycle to allow improvement in translation capacity and balance.
Objectives: To analyze the response to Fampridine in PPMS patients by evaluating the spatio-temporal changes measured by instrumental gait analysis (IGA).
Material and methods: 10 PPMS patients were analyzed by IGA and 12 speed standard spatial parameters in both right (R) and left (L) leg were recorded: normalized speed according leg length(VN), cadence (C), total time support (% TTA) -% of gait cycle and its distribution among one leg (AM) and first (% 1FS) and second double support (% 2DS). Results were compared to 12 healthy controls matched by age. Improvement was defined as approximate values to normal and was measured by the difference between the absolute values of Z-score pre-treatment and those obtained after 15 days of starting treatment with fampridine. The confidence interval was calculated at 95% average improvement bootstrap accelerated corrected for bias.
Results: After 15 days of daily treatment with fampridine most of the Z-score of all spatial variables improved statistically significantly except % 1FS (R) and % AM (R). The improvement is 0.69(L) / 0.41(R) VN, 1.21(L) / 0.83 (R) for C, 1.30 (L) / 1.34 (R) % TTA, 0.61(L) / 0.68(R)% 1FS, 0.32 (L) / 0.13 (R)% AM, and 0.19 (L) / 0,13 (R) for% 2DS.
Conclusions: Treatment with Fampridinedemonstrates a statically improvement in cadence, total time support and 2nd double support in both legs, and first double support time in left leg. These changes imply greater stability and balance during the stay and gait after treatment administration.
Disclosure:
Gonzalez Suárez I has received funding form Novartis, Biogen and Genzyme.
Pulido-VAldeolivas I: nothing to disclosure
Gomez-Andrés D: nothing to disclosure
Orviz-Garcia A: has received funding from Novartis
Montero-Atalaya A: nothing to disclosure
Martin-Gonzalo JA: nothing to disclosure
Rodríguez-Andonaegui I: nothing to disclosure
López de Velasco V has received funding form Genzyme
Rausell-tamayo E: nothing to disclosure
Oreja-Guevara C: has received fundings form Novartis, Genzyme, Biogen, Roche, Merck